Congenital agranulocytosis, also frequently referred to as Severe Congenital Neutropenia (SCN) or Kostmann syndrome, represents a group of rare genetic disorders characterized by a profound deficiency of circulating neutrophils from birth. This clinical condition is typically defined by an absolute neutrophil count (ANC) persistently below 500 cells per microliter. Pathologically, the marrow shows a maturation arrest of neutrophil precursors at the promyelocyte stage. Without treatment, such as granulocyte colony-stimulating factor (G-CSF), the condition is often fatal in early childhood due to life-threatening bacterial infections. Patients are also at an increased risk of developing myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) over time.
Specify the Absolute Neutrophil Count (ANC) to quantify the severity of the agranulocytosis.
Example: Patient with known Kostmann syndrome presents with an Absolute Neutrophil Count (ANC) of 150/mm3, indicating severe congenital agranulocytosis (D70.0). Currently stable on Filgrastim 5 mcg/kg daily. History of recurrent perianal abscesses managed surgically.
Billing Focus: Severity quantification and status of neutrophils for diagnostic specificity.
Identify specific genetic mutations such as ELANE, HAX1, or G6PC3 when confirmed by molecular testing.
Example: Genetic testing confirms a pathogenic variant in the ELANE gene. Patient has chronic congenital agranulocytosis (D70.0). Patient is high risk for infectious complications and is monitored quarterly for potential transformation to myelodysplastic syndrome.
Billing Focus: Etiological specificity linked to the primary diagnosis code.
Document associated manifestations such as gingivitis, stomatitis, or recurrent infections as complications of the agranulocytosis.
Example: Patient presents with necrotic gingivitis and aphthous ulcers. These are secondary manifestations of their primary congenital agranulocytosis (D70.0). No signs of systemic sepsis currently. Continuing prophylactic Sulfamethoxazole/Trimethoprim.
Billing Focus: Documentation of co-morbidities and secondary diagnoses linked to the primary neutropenic state.
Differentiate between congenital agranulocytosis and cyclic neutropenia to ensure correct ICD-10-CM selection.
Example: Neutrophil levels remain consistently below 200/mm3 without the 21-day oscillation pattern seen in cyclic neutropenia. Diagnosis remains congenital agranulocytosis (D70.0), not D70.4. Plan includes bone marrow aspiration to assess for maturation arrest.
Billing Focus: Differential diagnosis documentation to support the specific ICD-10-CM code.
Note the response to and dependency on Granulocyte Colony-Stimulating Factor (G-CSF) therapy.
Example: The patient is G-CSF dependent to maintain an ANC above 500/mm3. Diagnosis is severe congenital agranulocytosis (D70.0). Current dose of Filgrastim is titrated to 10 mcg/kg/day. Bone marrow biopsy from last month showed maturation arrest at the promyelocyte stage.
Billing Focus: Chronic therapy management and clinical response documentation.
Used for the initial complex evaluation of a neonate or child suspected of having congenital agranulocytosis.
Standard follow-up for monitoring ANC levels and titrating G-CSF therapy in a stable patient.
Management of a patient with congenital agranulocytosis presenting with a severe acute infection or suspected malignant transformation.
Required to identify maturation arrest at the promyelocyte stage to confirm D70.0.
Used in conjunction with aspiration to evaluate cellularity and morphology.
Essential laboratory test to monitor neutrophil levels (ANC).
Genetic confirmation of the most common form of congenital agranulocytosis.
Used for the administration of Filgrastim (G-CSF) in the clinical setting.
Morphological assessment of neutrophils to identify dysplastic features.
Used for simple injection-only visits or very stable, low-risk monitoring check-ins.